Overall Score

Revenue Quality

Gross margin remains exceptionally high at 90.8%, indicating strong product economics.

Revenue quality is supported by a 49.7% operating cash flow margin and 51.6% net profit margin.

Cash generation is solid with free cash flow yield of 5.9% and income quality of 0.96.

Profitability

Return on equity is healthy at 19.4%, but return on invested capital remains slightly negative at -0.6%.

Operating margin is negative at -2.9% despite strong EBITDA margin of 60.2%, suggesting meaningful below-EBITDA costs.

Interest coverage is negative at -2.6x, reflecting that EBIT is currently not covering interest expense on a TTM basis.

Balance Sheet

The balance sheet is very liquid with a current ratio of 13.5x and cash ratio of 7.1x.

Net debt is negative relative to EBITDA at -2.9x, indicating a net cash position.

Debt leverage is low with debt-to-equity of 0.13x and debt-to-assets of 8.2%.

Valuation

The stock trades at 6.7x EV/sales and 17.0x price to free cash flow, which is not cheap but not extreme for a profitable biotech business.

Earnings-based valuation is reasonable at 16.0x P/E given the current profitability profile.

Price-to-book of 3.0x suggests the market is paying a moderate premium to tangible equity.